Abstract
Objectives Siponimod is approved in Australia for adults with secondary progressive multiple sclerosis (SPMS). Initiating siponimod involves prescreening tests, including a CYP2C9 genotype test to determine siponimod dosing. To support onboarding, an integrated digital platform, ‘MSGo’, was developed by Novartis and RxMx® for Healthcare Professionals and multiple sclerosis patients. Here, data derived exclusively from MSGo is used to characterise onboarding of siponimod patients in Australia.
Methods The study will enrol 350–500 adults registered in MSGo for siponimod treatment. The primary endpoint is the average time for onboarding with key secondary endpoints addressing adherence and the variables that influence onboarding and adherence.
Results As of April 19th, 2021, 211 patients have enrolled in the RWE study, with baseline patient characteristics revealing more females than males (70% vs 30%) and a median age range of 51–60 years. A total of 88 patients initiated the first titration dose; 75 with ≥1 day of maintenance. Mixture-cure modelling estimated a median time to initiation of 53 days in the predicted population of patients who will ever initiate on siponimod. Patients who nominated a care partner at registration (n=27, 13%) appeared more likely to initiate siponimod earlier (p=0.017). The median time to receiving CYP2C9 genotype results from registration was 21 days (n=163, 95% CI:18–28 days). Of these, 87 patients listed their maintenance dose, with all selections following relevant dose recommendations.
Conclusions These interim results provide insights into siponimod onboarding for SPMS patients in Australia and demonstrate the utility of MSGo during a period challenged by COVID-19.
